Online citations, reference lists, and bibliographies.

The MiR-372-ZBTB7A Oncogenic Axis Suppresses TRAIL-R2 Associated Drug Sensitivity In Oral Carcinoma

Li-Yin Yeh, Cheng-Chieh Yang, Hsiao-Li Wu, Shou-Yen Kao, Chung-Ji Liu, Yi-Fen Chen, Shu-Chun Lin, Kuo-wei Chang
Published 2020 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
miR-372 has been shown a potent oncogenic miRNA in the pathogenesis of oral squamous cell carcinoma (OSCC). The zinc finger and BTB domain containing 7A protein (ZBTB7A) is a transcriptional regulator that is involved in a great diversity of physiological and oncogenic regulation. However, the modulation of ZBTB7A in OSCC remains unclear. Tissue analysis identifies a reverse correlation in expression between miR-372 and ZBTB7A in OSCC tumors. When OSCC cells have stable knockdown of ZBTB7A, their oncogenic potential and drug resistance is increased. By way of contrast, such an increase is attenuated by expression of ZBTB7A. Screening and validation confirms that ZBTB7A is able to modulate expression of the death receptors TRAIL-R1, TRAIL-R2, Fas and p53 phosphorylated at serine-15. In addition, ZBTB7A transactivates TRAIL-R2, which sensitizes cells to cisplatin-induced apoptosis. The ZBTB7A-TRAIL-R2 cascade is involved in both the extrinsic and intrinsic cisplatin-induced pathways of apoptosis. Database analysis indicates that the expression level of and the copy status of ZBTB7A and TRAIL-R2 are important survival predictors for head and neck cancers. Collectively, this study indicates the importance of the miR-372-ZBTB7A-TRAIL-R2 axis in mediating OSCC pathogenesis and in controlling OSCC drug resistance. Therefore, silencing miR-372 and/or upregulating ZBTB7A would seem to be promising strategies for enhancing the sensitivity of OSCC to cisplatin therapy.
This paper references
10.1038/nature15748
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer (2015)
10.1016/j.canlet.2016.07.035
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Jong-Lyel Roh (2016)
TRAILblazing strategies for cancer treatment.Cancers
AL Kretz (2019)
10.1016/j.canlet.2015.08.029
C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer.
Duan-bo Shi (2015)
10.1093/nar/gku501
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters
J. Loughery (2014)
10.1002/1878-0261.12376
miR‐372 and miR‐373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways
Lu‐Qin Wang (2018)
10.1111/odi.12304
Pokemon proto-oncogene in oral cancer: potential role in the early phase of tumorigenesis.
Davide Sartini (2015)
10.7150/thno.33598
A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors
Shu-yong Zhang (2019)
10.1158/0008-5472.CAN-15-1664
MicroRNA-211 Enhances the Oncogenicity of Carcinogen-Induced Oral Carcinoma by Repressing TCF12 and Increasing Antioxidant Activity.
Yi-Fen Chen (2016)
10.1101/gad.245910.114
ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.
Xue-Song Liu (2014)
implications for senescence
L Poliseno (2008)
10.1038/5517
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
H. Walczak (1999)
10.1186/1756-0500-2-175
SP1 enhances Zbtb7A gene expression via direct binding to GC box in HePG2 cells
Xuyu Zu (2009)
10.1038/nm.4463
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
M. Bezzi (2018)
10.1038/nrc.2018.11
The molecular landscape of head and neck cancer
C. René Leemans (2018)
10.1371/journal.pone.0135083
Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation
Yongmin Choi (2015)
10.1186/s40246-019-0252-0
The multi-faceted functioning portrait of LRF/ZBTB7A
Caterina Constantinou (2019)
10.1016/j.cell.2006.02.037
A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors
P. M. Voorhoeve (2006)
10.3390/cancers11040456
TRAILblazing Strategies for Cancer Treatment
Anna-Laura Kretz (2019)
10.1038/nature03203
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
T. Maeda (2005)
10.1093/carcin/bgu024
miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes.
Pei-Shih Hung (2014)
Characterization of 8 p 21 . 3 chromosomal deletions in B-cell lymphoma : TRAIL-R 1 and TRAIL-R 2 as candidate dosage-dependent tumor suppressor genes
F. Rubio-Moscardo (2005)
10.1002/ijc.31638
miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression.
Shih-Yuan Peng (2018)
Serum miR372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer
J Yu (1871)
The role of the 3D environment in hypoxia-induced drug and apoptosis resistance.
Jun W Kim (2011)
10.1371/journal.pone.0002542
The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence
L. Poliseno (2008)
10.1128/MCB.00520-06
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
D. Mérino (2006)
10.2174/1871520615666150716110406
Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer.
Jing Yu (2016)
10.1074/jbc.M405288200
Leukemia/Lymphoma-related Factor, a POZ Domain-containing Transcriptional Repressor, Interacts with Histone Deacetylase-1 and Inhibits Cartilage Oligomeric Matrix Protein Gene Expression and Chondrogenesis*
C. Liu (2004)
10.1186/1471-2407-11-54
Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma
Ming-hong Jiang (2010)
Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
S. Lee (1999)
miR31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma
CJ Liu (2010)
TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
F Rubio-Moscardo (2005)
10.1002/mc.22446
A Zbtb7a proto-oncogene as a novel target for miR-125a.
N. Hojo (2016)
10.1002/lary.25464
Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas.
Hsi-Feng Tu (2015)
10.1002/jbt.22169
MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a).
Xiao Liang (2018)
10.4161/auto.6.6.12423
Areca nut extract induced oxidative stress and upregulated hypoxia inducing factor leading to autophagy in oral cancer cells
H. Lu (2010)
10.1016/j.canlet.2011.09.040
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
Jing Zhao (2012)
10.1016/j.jfma.2017.04.022
Portland cement induces human periodontal ligament cells to differentiate by upregulating miR-146a.
Min-Ching Wang (2018)
10.1007/s12031-018-1179-y
Knockdown of miR-372 Inhibits Nerve Cell Apoptosis Induced by Spinal Cord Ischemia/Reperfusion Injury via Enhancing Autophagy by Up-regulating Beclin-1
Xigong Li (2018)
miR31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes.Carcinogenesis
PS Hung (2014)
10.1158/0008-5472.CAN-09-2291
miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma.
Chung-Ji Liu (2010)
10.1371/journal.pone.0099067
Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer
Haiji Wang (2014)
10.3389/fonc.2018.00245
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status
Hind Hafsi (2018)
10.1016/j.bbamcr.2017.12.006
TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Zuzana Nahácka (2018)
10.1016/S0304-3835(98)00230-4
Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.
Tadashi Arai (1998)
10.1016/j.nutres.2016.08.002
Nutrient restriction of glucose or serum results in similar proteomic expression changes in 3D colon cancer cell cultures.
Monica M. Schroll (2016)
A Zbtb7a proto-oncogene as a novel target formiR-125a.Mol Carcinog
N Hojo (2016)
10.1016/S1534-5807(03)00227-2
Embryonic stem cell-specific MicroRNAs.
H. Houbaviy (2003)
10.18632/oncotarget.25846
Interaction between N-cadherin and decoy receptor-2 regulates apoptosis in head and neck cancer
Phuong Thao Nguyen (2018)
10.4081/oncol.2017.332
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology
George E. Naoum (2017)
10.1182/blood-2005-05-2013
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
F. Rubio-Moscardo (2005)
10.1111/j.1600-0714.2004.00034.x
Establishment of OC3 oral carcinoma cell line and identification of NF-kappa B activation responses to areca nut extract.
Shu-Chun Lin (2004)
10.1002/hed.24035
TRAIL and TRAIL receptors in patients with laryngeal cancer.
Evren Erkul (2016)
A Zbtb 7 a proto - oncogene as a novel target formiR - 125 a
N Hojo (2016)
10.1002/jcp.26815
CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy.
Shengjiao Li (2018)
10.1016/j.redox.2019.101140
miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A
Yi-Fen Chen (2019)
10.1016/j.medin.2017.10.003
Systematic review and meta-analysis.
M. Delgado-Rodríguez (2018)
10.1177/0022034518762090
Predictive Prognostic Value of Tissue-Based MicroRNA Expression in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-analysis
Giuseppe Troiano (2018)
10.1139/bcb-2018-0303
LRF acts as an activator and repressor of the human β-like globin gene transcription in a developmental stage dependent manner.
Jin Kang (2018)
10.1038/onc.2010.23
Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs
Fabricio Loayza-Puch (2010)
10.1158/1541-7786.MCR-15-0169
ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM
Xue-Song Liu (2015)
10.1038/ng.2654
Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion
G. Wang (2013)
10.18632/ONCOTARGET.3659
Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1–miR-593-5p–MFF axis
Song Hai Fan (2015)
10.1101/gad.212258.112
Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.
Yan Chun Zhu (2013)
10.1016/j.neo.2017.08.008
ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity
Lu Zhang (2017)
10.3892/mmr.2017.8104
Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells.
Guang Sun (2018)
10.18632/ONCOTARGET.3340
miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo
Li-Yin Yeh (2015)
10.1016/j.cancergencyto.2006.01.007
Molecular cytogenetic analysis of oral squamous cell carcinomas by comparative genomic hybridization, spectral karyotyping, and fluorescence in situ hybridization.
K. Uchida (2006)
10.1371/journal.pone.0003215
The Evolving Transcriptome of Head and Neck Squamous Cell Carcinoma: A Systematic Review
Yau-Hua Yu (2008)
10.1177/0193945910394380
Systematic Review
F. Nabavi (2012)



Semantic Scholar Logo Some data provided by SemanticScholar